Clinical trial
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed…
NCT00452127 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00452127 |
|---|---|
| Title | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma |
| Official title | An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Have Been Treated With a Prior Rituximab-Containing Regimen |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | PRO131921 |
| Enrollment | 26 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2009 |
| First posted | Mar 27, 2007 |
| Last update posted | Jan 28, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: